Table 3.
Characteristics of the second genetic instrument (6 SNPs).
| SNP | Gene | Chr | Pos (GRCh37) | EA/OA | EAF | SNP-Exposure (coffee intake)* | SNP-Outcome (NAFLD) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Beta | SE | p | Beta | SE | p | ||||||
| rs2472297 | CYP1A2 | 15 | 75027880 | T/C | 0.24 | 0.13 | 0.007 | 1.74E–75 | −0.032 | 0.048 | 5.02E–01 |
| rs6968554 | AHR | 7 | 17287106 | G/A | 0.61 | 0.1 | 0.007 | 2.09E–45 | −0.035 | 0.044 | 4.25E–01 |
| rs17685 | POR | 7 | 75616105 | A/G | 0.29 | 0.06 | 0.007 | 2.15E–17 | −0.042 | 0.047 | 3.76E–01 |
| rs1481012 | ABCG2 | 4 | 89039082 | A/G | 0.89 | 0.054 | 0.009 | 1.57E–09 | −0.007 | 0.067 | 9.07E–01 |
| rs7800944 | MLXIPL | 7 | 73035857 | C/T | 0.28 | 0.052 | 0.009 | 6.11E–09 | −0.018 | 0.047 | 7.04E–01 |
| rs6265 | BDNF | 11 | 27679916 | C/T | 0.81 | 0.04 | 0.007 | 1.54E–08 | 0.073 | 0.054 | 1.82E–01 |
*
summary-level data were obtained from the meta-analysis of the individuals of European decent in both discovery and validation stages